/
KZIA
$14.46+$0.24 (+1.69%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$162.5M
11M shares
52-week range
$4.86 – $17.40
77% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
ADRC
Borrow rate
5.93%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-478.54
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.1K | $1.6K | $988.1K | $15.2M | $10.0K | $555 | $2.3M | $42.0K |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $13.1K | $1.6K | $988.1K | $15.2M | $10.0K | $555 | $2.3M | $42.0K |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| R&D | $9.8M | $6.5M | $9.5M | $14.5M | $20.2M | $15.6M | $17.4M | $7.3M |
| Operating income | −$12.5M | −$8.4M | −$12.2M | −$6.4M | −$25.4M | −$24.1M | −$28.5M | −$14.2M |
| EBITDA | −$10.8M | −$7.7M | −$11.1M | −$5.1M | −$23.5M | −$22.3M | −$26.6M | −$13.3M |
| Net income | −$6.0M | −$10.3M | −$12.5M | −$8.4M | −$25.0M | −$20.5M | −$26.8M | −$20.7M |
| Net margin | -46071.1% | -656230.0% | -1261.7% | -55.5% | -250140.0% | -3687419.8% | -1160.2% | -49290.5% |
| EPS (diluted) | -59.80 | -85.60 | -80.00 | -35.80 | -95.00 | -55.00 | -55.00 | -18.90 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $178413 | $-1.00 | $-1.35–$-0.66 | 1 |
| 2027 | $145000 | $-1.51 | $-2.03–$-1.00 | 1 |
| 2028 | $5M | $-1.96 | $-2.63–$-1.29 | 1 |
| 2029 | $43M | $0.17 | $0.11–$0.23 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Kazia Therapeutics Limited American Depositary Shares
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
www.kaziatherapeutics.com- Employees
- 6
- IPO / List date
- Jan 6, 1999
- HQ
- NEW SOUTH WALES 2113, C3
Held by traders on TradeandTell
No one on the platform currently holds KZIA.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in KZIA as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-04-17 | 1-for-5reverse |
| 2024-10-28 | 1-for-10reverse |
| 2017-07-14 | 1-for-4reverse |
Recent trades on TradeandTell
No one on the platform has traded KZIA yet.
